Status:
COMPLETED
Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding
Lead Sponsor:
Clinical Hospital Centre Zagreb
Conditions:
Bleeding
Hemoptysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Endobronchial bleeding is a relatively common complication of diagnostic bronchoscopy. Both tranexamic acid and adrenaline are used topically for the control of endobronchial bleeding. The aim of this...
Eligibility Criteria
Inclusion
- patients with endobronchial bleeding during diagnostic bronchoscopy that was not successfully controlled with cold (4°C) normal saline (3 aliquots of 5ml during 60sec)
Exclusion
- Any patient with a contraindication for diagnostic flexible bronchoscopy
- Coagulopathy (PV INR \>1.3)
- Thrombocytopenia (\<50x10\^9) or anemia (hgb \<80 g/L)
- Direct oral anticoagulant, low molecular weight heparin or antiplatelet drug therapy
- Thrombophilia, history of pulmonary embolism or deep vein thrombosis
- Contraindication for endobronchial application of adrenaline
- Coronary heart disease, cerebrovascular disease, history of tachyarrhythmia
- Uncontrolled pulmonary hypertension
- Cardiovascular decompensation
- Severe hypoxia (PaO2 \<60mmHg, SaO2 \<90% with an FiO2 \>=60%)
Key Trial Info
Start Date :
February 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2022
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04771923
Start Date
February 22 2021
End Date
February 4 2022
Last Update
February 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Hospital Centre Zagreb
Zagreb, Croatia, 10000